| Primary information |
|---|
| sequence ID | Seq_835 |
| Peptide sequence | ATEHLSTLSEKAKPALEDL |
| CancerPDF_ID | CancerPDF_ID70, CancerPDF_ID1072, CancerPDF_ID1585, CancerPDF_ID2510, CancerPDF_ID8580, CancerPDF_ID9549, |
| PMID | 16896061,16395409,21136997,21136997,23667664,21533267 |
| Protein Name | Apolipoprotein A-I,Apolipoprotein A-I,Apolipoprotein A-I,Apolipoprotein A-I,Aplipoprotein A-I,Apolipoprotein A-I |
| UniprotKB Entry Name | APOA1_HUMAN,APOA1_HUMAN,APOA1_HUMAN,APOA1_HUMAN,APOA1_HUMAN,APOA1_HUMAN |
| Fluid | Serum,Serum,Serum,Plasma,Serum,Serum |
| M/Z | 2052.89,2052.89,2052.0739,2052.0739,2052.07,685.03 |
| Charge | 1,1,1,1,1,3 |
| Mass (in Da) | 2053.07,NA,NA,NA,2054.31,NA |
| fdr | NA,NA,NA,NA,NA,NA |
| Profiling Technique | MALDI-TOF,MALDI-TOF,LC-MS,LC-MS,MALDI-TOF,LC-MS |
| Peptide Identification technique | Q/TOF MS/MS,Q/TOF/TOF and LC-MS/MS,LC-MS-MS/MS,LC-MS-MS/MS,FT-ICR MS/MS + nano-HPLC,LC/MS/MS |
| Quantification Technique | NA,NA,LC-ESI-MS,LC-ESI-MS,NA,Multiple Reaction Monitoring |
| Labelled/Label Free | Label Free,Label Free,Label Free,Label Free,Label Free,Label Free |
| FDR | NA,less than 1 “5,NA,NA,NA,1.49 |
| CancerPDF_ID | CancerPDF_ID70, CancerPDF_ID1072, CancerPDF_ID1585, CancerPDF_ID2510, CancerPDF_ID8580, CancerPDF_ID9549, |
| p-Value | 1.00E-05,5.75E-12,NA,NA,NA,NA |
| Software | MASCOT,MASCOT (v 2.0.04 for Windows),MASCOT(v. 2.2.01),MASCOT(v. 2.2.01),MASCOT,MASCOT |
| Length | 19,19,19,19,19,19 |
| Cancer Type | Metastatic thyroid carcinomas,"Advanced Prostate, Breast and Bladder cancer",Colorectal cancer,Normal,"Breast cancer, Lung cancer, Rectal cancer",Lung adenocarcinoma |
| Database | NCBI refseq Protein Database,NCBI refseq Protein Database,SwissProt Database,SwissProt Database,NA,Swissprot Database (57.4) |
| Modification | NA,NA,NA,NA,NA,NA |
| Number of Patients | 40 metastatic thyroid carcinoma patients and 40 normal for training phase and 10 metastatic thyroid carcinoma and 10 normal individuals for independent validation,"Advanced prostate (n = 32), breast (n = 21), and bladder (n = 20) cancer, 33 healthy in training test set, In validation set 41 independent serum samples from patients with advanced prostate cancer (prostate 2 [PR2])",30 patients and 30 healthy controls,27 healthy individuals,"Breast Cancer =84, lung cancer= 70, Rectal cancer = 30patients; 500 healthy",62 lung adenocarcinoma and 30 healthy control |
| Regulation | NA,"Upregulated in cancer vs normal with Ratio of median intensity (patients/Controls) =105, 306 and 1 in prostate, bladder and breast cancer respectively",NA,NA,NA,"Differentially expressed between earlier-stage lung cancer group (stage-I, II, and IIIa) vs normal" |
| Validation | Independent validation,Independent validation,Leave One out Cross validation,Leave One out Cross validation,NA,MRM-based validation of 19 candidates |
| Sensitivity | 95% on independent dataset,97.5% on independent validation dataset,NA,NA,NA,NA |
| Specificity | 95% on independent dataset,NA,NA,NA,NA,NA |
| Accuracy | NA,97.5 % on validation dataset,NA,NA,NA,NA |
| Peptide Atlas | NA |
| IEDB | |